---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-036164"
form_type: "8-K"
ticker: "MBRX"
cik: "0001659617"
company_name: "Moleculin Biotech, Inc."
filed_at: "2026-11-10T21:08:52+00:00"
generated_at: "2026-11-10T21:10:17.772925+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Moleculin: Annamycin plus PD-1 blockade extends survival in pancreatic cancer preclinical models

## Summary
- In an immunocompetent KPC mouse model of advanced pancreatic ductal adenocarcinoma, liposomal Annamycin (L-ANN) plus PD-1 blockade increased survival vs either agent alone; reconfirmed independently.
- Annamycin reached substantially higher and more sustained pancreatic tissue exposure than doxorubicin at the same dose, with increased CD8+ cytotoxic and CD4+ helper T-cell infiltration.
- Depleting CD8+ T cells shortened survival in treated mice, showing the immune system contributes to Annamycin's antitumor activity rather than being a bystander.
- Data presented Nov 10, 2026 by Waldemar Priebe, PhD of MD Anderson at the Marie Sklodowska-Curie Symposium in Tampa, building on AACR April and September 2026 results.
- CEO Walter Klemp said the priority remains the MIRACLE AML trial with a Q1 2027 data readout; Moleculin plans to sponsor an investigator-initiated pancreatic cancer trial in 2027.

## SEC filing metadata
- accession: 0001437749-26-036164
- form_type: 8-K
- ticker: MBRX
- cik: 0001659617
- company_name: Moleculin Biotech, Inc.
- filed_at: 2026-11-10T21:08:52+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1659617/000143774926036164/0001437749-26-036164-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1659617/000143774926036164/mbrx20261109_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-036164
- JSON: https://secwatch.observer/filing/0001437749-26-036164.json
- Plain text: https://secwatch.observer/filing/0001437749-26-036164.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.